News | June 07, 2021
Glenmark receives ANDA approval for theophylline extended-release tablets
Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets
Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
This marks Glenmark's first synthetic decapeptide injectable approval
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
The IPO comprises a fresh issue of up to Rs. 11,600 million and an offer for sale of up to 7,305,245 equity shares of Rs. 2 each of Glenmark Life Sciences by Glenmark Pharmaceuticals
Candid Powder brand is a market-leader in its category, with a market share of 64% in the medicated powder category.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
India business grew 11.8% YoY vs mid-single digit industry growth.
The jump in profit is due to the better performance of the API business.
Subscribe To Our Newsletter & Stay Updated
